Journal list Promote Sponsor
verified SJR 3,721 · Q1 • database Scopus / SJR & Web of Science indexed
Advanced Drug Delivery Reviews
Netherlands · Elsevier B.V.
workspace_premium Q1 — Pharmaceutical Science lock_open Open Access

Advanced Drug Delivery Reviews

Advanced Drug Delivery Reviews is a journal indexed in SJR in Pharmaceutical Science with an H index of 386. It has an SJR impact factor of 3,721 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 3,721.

Advanced Drug Delivery Reviews focuses its scope in these topics and keywords: drug, delivery, challenges, therapy, opportunities, conjugates, controlled, current, drugs, engineering, ...

ISSN: 0169-409X
Publisher: Elsevier B.V.
Category: Pharmaceutical Science
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
3,721 Q1
H-index 386
Acceptance rate pie_chart
17% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
NPD Open Access
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

3,721

H-index

386

Docs (year)

120

Docs 3y

798

Total refs

23955

Cites 3y

14339

Citable 3y

754

Cites/Doc 2y

16.97

Ref/Doc

199.63

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Applications of genetic engineering in veterinary medicine

View more

Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer

View more

Cyclodextrins in oligonucleotide delivery

View more

Confocal and probe microscopy to study gene transfection mediated by cationic liposomes with a cationic cholesterol derivative

View more

Computer systems for the prediction of toxicity: an update

View more

Co-delivery of chemotherapeutics and proteins for synergistic therapy

View more

Co-culture systems for vascularization - Learning from nature

View more

Closed-loop insulin delivery - the path to physiological glucose control

View more

Challenges of turning nucleic acids into therapeutics

View more

Challenges in the clinical assessment of novel tuberculosis drugs

View more

Cells for drug delivery platforms

View more

Bioreductive and gene therapy approaches to hypoxic diseases

View more
SHOW MORE ARTICLES

Biodegradable implant strategies for inhibition of restenosis

View more

A novel non-viral gene transfer system, polycation liposomes

View more

Antisense drug delivery through the blood-brain barrier

View more

Alkylating agent prodrugs for ADEPT

View more

Advances in targeted delivery

View more

Advances in lipid-based drug solubilization and targeting

View more

Advanced Drug Delivery Reviews Cornerstone in the stimulation and dissemination of innovative drug delivery research

View more

Adenovirus-mediated gene transfer to liver11The article was originally published in Advanced Drug Delivery Reviews 17 (1995) 303-307.

View more

Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics

View more

A timely re-examination of drug polymorphism in pharmaceutical development and regulation

View more

A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery

View more

A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth® liposome-encapsulated tumor necrosis factor-a and cytotoxic agents

View more

FAQs